Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…

What’s Driving the Pain? Alternative Approaches to Pain Management
Patients can experience many different types of pain, and some patients with chronic pain may believe that only opioids will help them. According to Kelly Weselman, MD, the best way to begin managing pain is to determine its root cause and communicate with the patient about the best approach(es) for decreasing their specific pain…

Stem Cell Transplantation Benefits Patients with Scleroderma
A recently published study gives new insight into an innovative approach to treating patients with severe scleroderma and internal organ involvement. During the six-year study, researchers demonstrated the durability of the beneficial effects of stem cell transplantation in this patient population. Their data also suggest the treatment has the potential to renormalize the autoreactive immune system…
Blacks in U.S. Lose Quality of Life Due to Fewer Knee Replacements
(Reuters Health)—Black people with knee osteoarthritis may have a worse quality of life than white patients in part because they’re less likely to be offered knee replacement surgery or to get the procedure when it’s recommended, a U.S. study suggests. Knee replacement surgery has the potential to greatly relieve suffering from severe joint pain that…
U.S. to Extend Skimpy Health Insurance Outside of Obamacare
WASHINGTON/NEW YORK (Reuters)—The U.S. government on Tuesday proposed extending the availability of skimpy health insurance plans to millions of Americans in another Trump administration move aimed at undercutting the requirements of the Affordable Care Act, often called Obamacare. The U.S. Department of Health and Human Services issued a proposed rule that such plans, now available…
Baricitinib Also Appears Effective in Biologic-Refractory RA
NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…

Is Patient-Centered Care Effective for Rheumatology?
Patient-centered care requires increased communication and a proactive patient. But how does it benefit a rheumatology practice? According to Stanford Shoor, MD, patient-centered care offers a team-based approach that can improve satisfaction in care and positively affect RA-specific outcomes…

Gene Signatures in IgG4-Related Disease
Research suggests prednisone treatment can selectively modulate the signatures of regulatory T (Treg) cells, eosinophils and neutrophils in patients with IgG4-related disease. The results show IgG4-related disease may result from an imbalance of immune and inflammatory cells…

Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead
The FDA recently expanded the indications for ferumoxytol injections to include the treatment of adults with iron-deficiency anemia…

The New Tax Bill’s Implications for Healthcare
On Dec. 20, 2017, Congress passed a massive tax bill that will have an impact on nearly every individual and business in America. The bill makes sweeping revisions to existing tax provisions, and it will largely affect the health industry. Individual Mandate Repealed The bill repeals the individual mandate established in 2005 by the Affordable…
- « Previous Page
- 1
- …
- 362
- 363
- 364
- 365
- 366
- …
- 821
- Next Page »